
News|Articles|November 5, 2025
6 Psychiatry Headlines You Missed in October 2025
Author(s)Chelsie Derman
Fact checked by: Abigail Brooks, MA
This month in review spotlights the top psychiatry news from October 2025, featuring FDA's approval of UZEDY for bipolar I disorder.
Advertisement
Advertisement
From a new long-acting injectable for bipolar I disorder to a digital therapeutic targeting schizophrenia’s negative symptoms, October brought a wave of innovation in
Related to this article

Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.

Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Advertisement
Advertisement

